Apunte histórico sobre la quinidina

Margarita Dorantes Sánchez

Texto completo:

PDF PDF (English)

Resumen

Apunte histórico sobre la quinidina

Referencias

Belhassen B. Is quinidine the ideal drug for Brugada syndrome? Heart Rhythm. 2012;9(12):2001-2.

Yang F, Hanon S, Lam P, Schweitzer P. Quinidine revisited. Am J Med. 2009;122(4):317-21.

Viskin S. Idiopathic ventricular fibrillation "Le syndrome d'Haissaguerre" and the fear of J waves. J Am Coll Cardiol. 2009;53(7):620-2.

Selzer A, Wray HW. Quinidine syncope, paroxysmal ventricular fibrillation ocurring during treatment of chronic atrial arrhythmias. Circulation. 1964;30(1):17-26.

Márquez MF, Bonny A, Hernández-Castillo E, De Sisti A, Gómez-Flores J, Nava S, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm. 2012;9(12):1995-2000.

RuDusky BM. Quinidine as an antiarrhythmic. Chest. 2001;119(5):1617-8.

Viskin S, Wilde AAM, Guevara-Valdivia ME, Daoulah A, Krahn AD, Zipes DP, et al. Quinidine, a life-saving medication for Brugada syndrome, is inaccesible in many countries. J Am Coll Cardiol. 2013;61(23):2383-7.

Antzelevitch C, Fish JM. Therapy for the Brugada syndrome. En: Kass RS, Clancy CE eds. Basis and treatment of cardiac arrhythmias. New York: Springer-Verlag Berlín Heidelberg, 2006; p. 305-30.

Olsson G. Market withdrawal of quinidine bisulfate (kinidin durules) in 2006. Heart Rhythm. 2010;7(6):864.

Belhassen B, Glick A, Viskin S. Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. Pacing Clin Electrophysiol. 2009;32(3):294-301.

Viskin S, Antzelevitch C, Márquez MF, Belhassen B. Quinidine: a valuable medication joins the list of "endangered species". Europace. 2007;9(12):1105-6.

Viskin S, Wilde AAM, Tan HL, Antzelevitch C, Shimizu W, Belhassen B. Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm. 2009;6(3):401-4.

Viskin S, Belhassen B, Wilde AAM. Irreplaceable antiarrhythmic medications are disappearing: the case of quinidine. Heart Rhythm. 2010;7(6):863.

Estes NAM, Page RL. Response – Irreplaceable antiarrhythmic medications are disappearing: the case of quinidine. Heart Rhythm. 2010;7(6):863-4.

Vardas PE, Kanoupakis EM. Old drugs never die; they just fade away. Heart Rhythm. 2010;7(6):864.

Adler A, Nordkamp LO, Crotti L, Schwartz P, Castelletti S, Veltmann C, et al. Empiric quinidine for asymptomatic Brugada syndrome – Preliminary results of an international registry. Heart Rhythm. 2012;9(11):1918-9.

Laurent G, Saal S, Amarouch MY, Béziau DM, Marsman RFJ, Faivre L, et al. Multifocal ectopic Purkinje-related premature contractions. A new SCN5A-related cardiac channelopathy. J Am Coll Cardiol. 2012;60(2):144-56.

Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation. 1999;100(15):1660-6.

Alings M, Dekker L, Sadee A, Wilde A. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol. 2001;24 (9 Pt 1):1420-2.

Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol. 1999;10(10):1301-12.

Belhassen B, Viskin S, Antzelevitch C. The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin Electrophysiol. 2002;25(11):1634-40.

Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol. 2004;43(10):1853-60.

Mok NS, Chan NY, Chiu AC. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol. 2004;27(6 Pt 1):821-3.

Belhassen B, Viskin S. Pharmacologic approach to therapy of Brugada syndrome: quinidine as an alternative to ICD therapy?. En: Antzelevitch C, Brugada P, Brugada J, Brugada R, eds. The Brugada syndrome: from bench to bedside. Oxford: Blackwell Futura, 2004; p. 202-11.

Enlaces refback

  • No hay ningún enlace refback.


Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.